Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Respiratory Syncytial Virus Disease

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inhibition of placental trophoblast fusion by guanylate-binding protein 5.

Science advances·2025

Same author

Direct translation of incoming retroviral genomes.

Nature communications·2024

Same author

Vpx enhances innate immune responses independently of SAMHD1 during HIV-1 infection.

Retrovirology·2021

Same author

HIV-1 Is a Poor Inducer of Innate Immune Responses.

mBio·2019

Same author

NP220 mediates silencing of unintegrated retroviral DNA.

Nature·2018

Same author

Cyclin-dependent kinase activity is required for type I interferon production.

Proceedings of the National Academy of Sciences of the United States of America·2018

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Motavizumab.

¹Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA. oya.cingoz@tufts.edu

|January 13, 2010

Summary

This summary is machine-generated.

Motavizumab, a new monoclonal antibody, shows effectiveness in preventing respiratory syncytial virus (RSV) in high-risk infants. This advanced treatment is currently under FDA review for RSV prophylaxis.

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens

Published on: February 14, 2011

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Area of Science:

Immunology
Virology
Pharmacology

Background:

Respiratory syncytial virus (RSV) poses a significant health burden, particularly in high-risk infant populations.
Existing prophylaxis options have limitations, necessitating the development of more effective treatments.
Monoclonal antibodies (mAbs) have emerged as a promising strategy for viral prophylaxis.

Purpose of the Study:

To evaluate the efficacy and safety of Motavizumab (MEDI-524, Numax) for respiratory syncytial virus (RSV) prophylaxis.
To assess Motavizumab's performance as a second-generation monoclonal antibody derived from palivizumab (Synagis).
To determine the potential of Motavizumab in reducing the disease burden associated with RSV in vulnerable infant populations.

Main Methods:

Motavizumab, a humanized IgG1 kappa monoclonal antibody, was developed using affinity maturation techniques.
Large-scale clinical studies were conducted to evaluate Motavizumab's efficacy and safety profile.
The study focused on high-risk infant populations susceptible to severe RSV disease.

Main Results:

Motavizumab demonstrated significant efficacy in reducing the overall disease burden of RSV.
Clinical studies indicated a favorable safety profile for Motavizumab in the target population.
The data supports Motavizumab's potential as an effective intervention for RSV prevention.

Conclusions:

Motavizumab represents a promising advancement in the prophylaxis of respiratory syncytial virus (RSV).
The drug's demonstrated efficacy and safety profile warrant its consideration for clinical use in high-risk infants.
Motavizumab's development signifies progress in leveraging monoclonal antibody technology for infectious disease prevention.